Atezolizumab Triplet Therapy for BRAF V600-Mutant Melanoma: Paolo A. Ascierto, MD
Sarah Williams, MAT
Expert Analysis
Recently, the FDA approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) and cobimetinib (Cotellic®, Genentech) for the treatment of BRAF V600-mutant advanced melanoma. In this interview with i3 Health, Paolo A. Ascierto, MD, principal investigator of the IMspire1...
​Connecting With Patients With Cancer in Spite of COVID-19: Kiri A. Cook, MD
Sarah Williams, MAT
Expert Analysis
The stress of having cancer and the physical and financial toll of treatment can be difficult for patients, even under normal circumstances. During the COVID-19 pandemic, patients face additional stressors, including not only the fear of mortality from COVID-19 but also the emotional impact of isolation. This sense of isolation can be pre...
IVC Filter Efficacy in Patients With Cancer and Deep Vein Thrombosis: Rahul A. Sheth, MD
Sarah Williams, MAT
Expert Analysis
Patients with cancer are at substantially increased risk for deep vein thrombosis (DVT) and resulting pulmonary embolism. Together, these two forms of venous thromboembolism constitute the second leading cause of death for patients with known malignancies. The standard of care for DVT is anticoagulation, yet many patients with cancer and DVT are un...
Cancer Overscreening in Older Adults: Jennifer L. Moss, PhD
Keira Smith
Expert Analysis
According to a study recently published in JAMA Network Open, a high proportion of older adults with average cancer risk are overscreened for colorectal, cervical, and breast cancers after surpassing specified upper age limits recommended by the US Preventive Services Task Force (USPSTF). In this interview, Jennifer L. Moss, PhD, first author of th...
Oral Decitabine/Cedazuridine for MDS: Olatoyosi Odenike, MD
Keira Smith
Expert Analysis
In this interview, Olatoyosi Odenike, MD, speaks with i3 Health about the approval of oral decitabine/cedazuridine (Inqovi®, Astex Pharmaceuticals, Inc.) for adult patients with myelodysplastic syndromes (MDS). Dr. Odenike, Director of the Leukemia Program at the University of Chicago and an investigator of one of the clinical trials on which the a...
Breast Cancer Chemotherapy in Older Patients With Comorbidities: Nina Tamirisa, MD
Sarah Williams, MAT
Expert Analysis
Many older patients with breast cancer have significant comorbidities, increasing the challenges of treatment. These challenges are compounded by the fact that elderly patients with multiple comorbidities are frequently excluded from participating in clinical trials, resulting in a lack of treatment data for this population. Nina Tamirisa, MD, and ...
Lurbinectedin for Small-Cell Lung Cancer: Luis Paz-Ares, MD
Sarah Williams, MAT
Expert Analysis
Last month, the FDA granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer experiencing disease progression on or after platinum-based chemotherapy. In this interview, Luis Paz-Ares, MD, principal investigator of the phase 2 basket trial PM1183-B-005-14 (Study B-005; NCT0245497...
Murray Brunt, MBBS on 10-Year Results of FAST: 5-Fraction RT for Breast Cancer
Emily Levitch
Expert Analysis
Ten-year results from the FAST study show that there are no significant differences in normal tissue effects (NTE) rates after 28.5 Gy/5 fractions (fr) compared with 50 Gy/25 fr in patients with early breast cancer; however, NTE were higher with 30 Gy/5 fr, according to a study published in the Journal of Clinical Oncology. In an interview with i3 ...
John Leonard, MD: FDA Approval of Selinexor for DLBCL
Emily Levitch
Expert Analysis
Selinexor (Xpovio®, Karyopharm Therapeutics) was recently FDA approved to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This approval extends to patients with DLBCL that resulted from follicular lymphoma and those who had previously received at least two prior lines of systemic therapy. John Leonard, MD, the Richard T. Silver Dis...
Hypertensive Medications and Reduced Colorectal Cancer Risk: Wai K. Leung, MD
Keira Smith
Expert Analysis
In this interview, Wai K. Leung, MD, speaks with i3 Health about his research team's finding, recently published in Hypertension, that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with a decreased risk of colorectal cancer within three years of colonoscopy. Dr. Leung discusses the significan...
Avelumab for Urothelial Carcinoma: An Interview With Thomas Powles, MBBS, MRCP, MD
Emily Levitch
Expert Analysis
The FDA recently approved avelumab (Bavencio®, EMD Serono, Inc.) for patients with advanced urothelial carcinoma (UC). Thomas Powles, MBBS, MRCP, MD, discusses with i3 Health the implication of this approval and future steps for research and offers community oncologists advice on treating this patient population. What are the most challenging aspec...
The Changing Standards for FDA Oncology Approvals: Talal Hilal, MD
Sarah Williams, MAT
Expert Analysis
The FDA approval process is in place to ensure that drugs are safe and effective before they are made available to the public. But do the clinical trials that lead to approval truly ascertain whether a drug is efficacious? Fully two-thirds of anticancer drug clinical trials leading to FDA approvals between 2014 and 2019 had at least one import...
Successfully Treating Kaposi Sarcoma: Robert Yarchoan, MD
Sarah Williams, MAT
Expert Analysis
Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI), recently spoke with i3 Health about the approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV. In this second installment of his interview, Dr. Yarchoan shares valuable advice with oncologists as they ...
Burosumab-twza for Tumor-Induced Osteomalacia: Suzanne Jan de Beur, MD
Keira Smith
Expert Analysis
In this interview with i3 Health, Suzanne Jan de Beur, MD, discusses the recent approval of burosumab-twza (Crysvita®, Ultragenyx Pharmaceutical, Inc.), for patients with tumor-induced osteomalacia (TIO) whose tumors are unable to be localized or resected. Dr. Jan de Beur, lead investigator of one of the phase 2 clinical trials on which the approva...
Gemtuzumab Ozogamicin for Pediatric Acute Myeloid Leukemia: Alan S. Gamis, MD, MPH
Keira Smith
Expert Analysis
In this interview, Alan S. Gamis, MD, MPH, speaks with i3 Health about the recent FDA approval of gemtuzumab ozogamicin (MylotargTM, Wyeth Pharmaceuticals, LLC) for pediatric patients aged 1 month and older with newly diagnosed CD33-positive acute myeloid leukemia (AML). Dr. Gamis, lead investigator of the phase 3 Children's Oncology Group Trial AA...
Treatment Advances in Gastrointestinal Stromal Tumor: Margaret von Mehren, MD
Sarah Williams, MAT
Expert Analysis
The treatment of gastrointestinal stromal tumor (GIST), a rare tumor type with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, has seen exciting advances this year, first with the FDA's approval of avapritinib for metastatic GIST with platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, and mor...
Ken Kato, MD, PhD: FDA Approval of Nivolumab for Esophageal Squamous Cell Carcinoma
Emily Levitch
Expert Analysis
The FDA recently approved nivolumab for patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior fluoropyrimidine- and platinum-based chemotherapy. Ken Kato, MD, PhD, lead author on the study the approval was based on, spoke to i3 Health about the challenges of treating this pat...
Metronomic Capecitabine Maintenance for TNBC: Zhongyu Yuan, MD
Emily Levitch
Expert Analysis
Metronomic capecitabine maintenance therapy has been shown to be more effective compared with observation for patients with triple-negative breast cancer (TNBC), according to a study led by Zhongyu Yuan, MD. Results of the study have been presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. In this intervie...
Rucaparib for BRCA-Mutated Castration-Resistant Prostate Cancer: Nicholas Vogelzang, MD
Keira Smith
Expert Analysis
In this interview, Nicholas Vogelzang, MD, speaks with i3 Health about the recent FDA approval of rucaparib (Rubraca®, Clovis Oncology, Inc.) for the treatment of patients with metastatic BRCA-mutated castration-resistant prostate cancer (CRPC) who previously received one line of taxane-based chemotherapy and at least one line of androgen receptor-...
Pomalidomide for Kaposi Sarcoma: Robert Yarchoan, MD
Sarah Williams, MAT
Expert Analysis
The FDA's recent accelerated approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV marked the first approval for this cancer in over 20 years. In this interview with i3 Health, Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI) and principal investigato...

Copyright © 2022 Oncology Data Advisor. All rights reserved.